VPC
Vestal Point Capital Portfolio holdings
AUM
$1.9B
1-Year Return
12.28%
This Quarter Return
-2.24%
1 Year Return
-12.28%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$1.69B
AUM Growth
+$419M
(+33%)
Cap. Flow
+$502M
Cap. Flow
% of AUM
29.74%
Top 10 Holdings %
Top 10 Hldgs %
42.19%
Holding
93
New
24
Increased
33
Reduced
11
Closed
18
Top Buys
| 1 |
Merck
MRK
|
$79.6M |
| 2 |
Nuvalent
NUVL
|
$47M |
| 3 |
Vera Therapeutics
VERA
|
$45.5M |
| 4 |
Cytokinetics
CYTK
|
$40M |
| 5 |
Ascendis Pharma
ASND
|
$37.2M |
Top Sells
| 1 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
$63.9M |
| 2 |
Insmed
INSM
|
$48.3M |
| 3 |
Agios Pharmaceuticals
AGIO
|
$33.8M |
| 4 |
uniQure
QURE
|
$30.5M |
| 5 |
Janux Therapeutics
JANX
|
$22M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Globus Medical
GMED
$8.14B
| $26.9M | 1.59% |
+325,000
| New | +$26.9M |
|
27
Dianthus Therapeutics
DNTH
$794M
| $23.4M | 1.39% |
1,075,000
+680,000
| +172% | +$14.8M |
|
|
NYXH
28
Nyxoah
NYXH
$214M
| $23.4M | 1.39% |
+2,924,216
| New | +$23.4M |
|
|
VRNA
29
Verona Pharma
VRNA
$9.19B
| $23M | 1.36% |
+495,000
| New | +$23M |
|
30
Ionis Pharmaceuticals
IONS
$9.46B
| $20.8M | 1.23% |
+595,000
| New | +$20.8M |
|
31
Liquidia Corp
LQDA
$2.48B
| $20.7M | 1.23% |
1,760,000
+260,000
| +17% | +$3.06M |
|
32
Day One Biopharmaceuticals
DAWN
$759M
| $18.2M | 1.08% |
1,440,000
-1,060,000
| -42% | -$13.4M |
|
33
UroGen Pharma
URGN
$870M
| $17.4M | 1.03% |
1,630,000
+1,230,000
| +308% | +$13.1M |
|
34
Legend Biotech
LEGN
$6.46B
| $15.5M | 0.92% |
475,000
+350,000
| +280% | +$11.4M |
|
35
Roivant Sciences
ROIV
$8.58B
| $14.8M | 0.88% |
+1,250,000
| New | +$14.8M |
|
36
Regeneron Pharmaceuticals
REGN
$60.1B
| $14.2M | 0.84% |
+20,000
| New | +$14.2M |
|
37
Establishment Labs
ESTA
$1.12B
| $13.8M | 0.82% |
300,000
+260,000
| +650% | +$12M |
|
38
Tyra Biosciences
TYRA
$647M
| $13.8M | 0.82% |
+990,000
| New | +$13.8M |
|
|
BCAX
39
Bicara Therapeutics Inc. Common Stock
BCAX
$658M
| $12.4M | 0.73% |
710,000
+285,000
| +67% | +$4.96M |
|
40
Black Diamond Therapeutics
BDTX
$163M
| $12M | 0.71% |
5,600,000
+571,500
| +11% | +$1.22M |
|
41
Solid Biosciences
SLDB
$433M
| $11.4M | 0.68% |
2,850,000
+50,000
| +2% | +$200K |
|
42
Agilent Technologies
A
$36.4B
| $10.1M | 0.6% |
75,000
-25,000
| -25% | -$3.36M |
|
43
Applied Therapeutics
APLT
$67M
| $9.85M | 0.58% |
11,500,000
+10,355,000
| +904% | +$8.87M |
|
44
Perrigo
PRGO
$3.2B
| $9.64M | 0.57% |
+375,000
| New | +$9.64M |
|
45
Nurix Therapeutics
NRIX
$697M
| $9.14M | 0.54% |
485,000
+60,000
| +14% | +$1.13M |
|
46
Lexeo Therapeutics
LXEO
$268M
| $7.9M | 0.47% |
1,200,000
+350,000
| +41% | +$2.3M |
|
47
Zai Lab
ZLAB
$3.34B
| $7.86M | 0.47% |
+300,000
| New | +$7.86M |
|
48
Celldex Therapeutics
CLDX
$1.51B
| $7.71M | 0.46% |
+305,000
| New | +$7.71M |
|
49
Voyager Therapeutics
VYGR
$215M
| $6.97M | 0.41% |
1,230,000
+740,000
| +151% | +$4.2M |
|
|
ITOS
50
DELISTED
iTeos Therapeutics
ITOS
| $6.91M | 0.41% |
900,000
-125,000
| -12% | -$960K |
|